Nordic Issuing

Ongoing case

Lipigon Pharmaceuticals AB

Back to all cases

Lipigon Pharmaceuticals AB

3 Jun - 17 Jun 2022Rights issue

Lipigon Pharmaceuticals AB was founded in 2010 by researchers at Umeå University and is based on over 50 years of research in lipid biology (fats). In total, approximately SEK 50m has been invested in the company since the start, of which SEK 36m consisted of cash share issues and SEK 14m of project support from, among others, the EU and Vinnova. At the end of 2016, the first external investments came. Since then, several important milestones have been reached, including collaborations and important steps in development projects. In 2019, Lipigon moved from the university to its own laboratories and offices. Today, eight people work in the company, corresponding to about six full-time positions.

Read more on the company's website

The offer in summary

Record date: 1 June 2022

Subscription period: 3 June - 17 June 2022

Subscription rights: Those who on the record date of June 1, 2022 is registered as shareholder have the right to subscribe for shares in the Rights Issue and will receive one (1) subscription right for each share held. Five (5) subscription rights entitles the holder to subscribe for six (6) new shares.

Subscription price: SEK 2.15

Emission volume: Maximum of 11 679 474 shares which corresponds to about SEKm 25

Trading with subscription rights: 7 June - 14 June 2022

Marketplace: Nasdaq First North Growth Market

Financial advisor: Stockholm Corporate Finance




Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.